Can we afford to eliminate restenosis? Can we afford not to?
about
Combining short stent implantation and drug-eluting stenting for routine use yields a low restenosis rateRationale and study design of the CardioGene Study: genomics of in-stent restenosis.Economic evaluation of sirolimus-eluting stents.Economic evaluation of strategies to reduce sudden cardiac death in young athletes.Effect of hospital ownership status and payment structure on the adoption and use of drug-eluting stents for percutaneous coronary interventionsShortening the stent length reduces restenosis with bare metal stents: matched pair comparison of short stenting and conventional stenting.Vascular restenosis - striving for therapy.An evidence-based approach to the use of drug-eluting stents in clinical practice.Decision models for assessing the cost effectiveness of drug-eluting stents.Drug-eluting stents: from evidence to policy.Restenosis related to percutaneous coronary intervention has been solved?Efficacy and safety of drug-eluting stents: current best available evidence.Promoting vascular regeneration as an alternative to conventional angioplasty-based intervention.The cost-effectiveness of drug-eluting stents: a systematic review.The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review.Short stent implantation for routine use is feasible in a high proportion of coronary interventions and yields a low restenosis rate.Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial.Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.Role of magnolol in the proliferation of vascular smooth muscle cells.Dollars and stents: the economics of drug-eluting stents.Combining short stent implantation and drug-eluting stenting for routine use yields a low restenosis rate.Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: A cost-effectiveness study
P2860
Q25257554-EBE7B5A4-C2FD-4758-AF9A-1DF709AB4443Q31119076-C94862D5-2D2E-49B8-9909-6F8F477D3024Q33759433-ACD56C68-6791-4C89-B76A-FB89F9E6F481Q33819489-8A6DEFD8-C011-457B-9D20-CFD4EABD507DQ35575044-B4AB44F6-B9AB-4CB6-99A8-61772C2A07EAQ35771873-C85BC1DF-EBC6-44D0-B7A0-6596E742A5EBQ35925488-1D928971-3909-4A99-A867-C740E06746ADQ36086606-ADBB6E95-3D6A-4AAB-B6BF-89178038DFFCQ36161276-EA590C10-A8B5-4548-9161-DAA80F2698AAQ36314909-29D91248-6BB2-4EDB-A4D8-344EF752AF6DQ36486769-61D0D65B-C370-4860-B672-F5164C8712CEQ36639071-13B284D5-702F-432B-AEA4-A880AE957C8AQ36684479-B38CC7A8-594E-4E01-A938-F330DEED31CBQ36688107-C8B17728-C9C8-4776-9C43-44AD763DF898Q36735675-35B2E2BB-3006-4E2E-B3FA-88E7411A942EQ40429734-A80F91CF-0B17-475A-9799-C0E2536CE41CQ45287552-AF94C857-715C-4C57-A371-810FA678F909Q45846827-9808FE2E-1FFE-4A02-8D4F-164D3EA36510Q46923811-49D0E583-1224-40D8-814B-642B632AEF81Q51484880-B147FD9B-149E-48E0-967D-58D8B6BAFBA9Q53767304-3408063D-C3A2-40D6-95DC-4CB06D8F43AFQ57446615-EB6F243D-BF8C-4A79-8BFC-2BF7F46194C8
P2860
Can we afford to eliminate restenosis? Can we afford not to?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Can we afford to eliminate restenosis? Can we afford not to?
@en
Can we afford to eliminate restenosis? Can we afford not to?
@nl
type
label
Can we afford to eliminate restenosis? Can we afford not to?
@en
Can we afford to eliminate restenosis? Can we afford not to?
@nl
prefLabel
Can we afford to eliminate restenosis? Can we afford not to?
@en
Can we afford to eliminate restenosis? Can we afford not to?
@nl
P1476
Can we afford to eliminate restenosis? Can we afford not to?
@en
P2093
Ameet Bakhai
David J Cohen
P304
P356
10.1016/J.JACC.2003.11.020
P407
P577
2004-02-01T00:00:00Z